NGN-401 Embolden™ Trial is Fully Enrolled
Neurogene shared an update on their NGN-401 program for Rett syndrome, including progress from their ongoing clinical trial and what’s ahead.
Progress on the clinical trial:
-
Current clinical trial (“Embolden”) is fully enrolled, and more than half of patients have already received the treatment.
-
The company expects to finish dosing all patients by mid-2026.
-
So far, the treatment has been generally well-tolerated, with no serious immune-related cases (HLH) at the tested dose.
Regulatory & Development Milestones:
-
The U.S. FDA gave NGN-401 Breakthrough Therapy designation, which can speed up development and review.
-
Neurogene is preparing to apply for approval (a Biologics License Application, or BLA).
-
Manufacturing is already aligned with commercial scale, which simplifies the approval process.
What’s Expected in 2026:
- Finish dosing patients in the main trial (by mid-2026)
- Release updated clinical data (mid-2026)
- Begin final manufacturing validation
- Continue preparing for potential launch
We’ll continue to follow progress as more data becomes available.
